10-K: Nowtransit Inc. Reports Full Year 2023 Results, Highlights Reverse Merger and Growth Initiatives

Nowtransit Inc.'s 2023 annual report details a reverse merger, increased revenue, and a net loss, alongside plans for future growth in the health and wellness market.

Summary

• Nowtransit Inc. reported a net loss of $251,500 for the year ended December 31, 2023, compared to a net loss of $170,450 in 2022.
• The company's revenue increased significantly to $597,595 in 2023 from $69,343 in 2022, driven by overall company growth.
• General and administrative expenses rose to $706,257 in 2023 from $151,319 in 2022, due to costs associated with SEC reporting, marketing, and the reverse merger.
• A reverse merger with Best 365 Labs Inc. was completed on March 10, 2023, resulting in a change of control and a shift in business focus to clinically-tested health products.
• The company is currently marketing products including Be On-Guard Mouth Spray, Be On-Guard Nasal Spray, EZ Safer Surface Cleaner, Be On-Guard Brain Fog Support, ADHD 365, NeuroPro Plus, TBI-365, and Metabolism+.
• Nowtransit is pursuing a private placement to raise up to $1,000,000 and plans to file Form 1-A with the SEC.
• The company is targeting various market opportunities including dementia, ADHD, long COVID, general energy, traumatic brain injury, mild cognitive decline, GLP-1 weight loss, sleep improvement, epilepsy, and nasal health.
• As of December 31, 2023, the company had total assets of $93,388, including cash, accounts receivable, and inventory.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is significant revenue growth and a strategic shift in business focus, the increased net loss, material weaknesses in internal controls, and going concern issues temper the positive aspects. The company is in a high-risk, high-reward situation.

Positives

• The company experienced a substantial increase in revenue, growing from $69,343 in 2022 to $597,595 in 2023.
• The reverse merger with Best 365 Labs Inc. has provided a new business direction and product line.
• Nowtransit has a diverse product portfolio targeting multiple health and wellness markets.
• The company has a medical advisory team and a sales and marketing team in place.
• The company has a provisional patent application for its Methylene Blue products.
• The company is actively pursuing multiple sales channels, including Amazon, wholesale, private label, and direct sales.

Negatives

• The company reported a net loss of $251,500 for 2023, an increase from the $170,450 loss in 2022.
• General and administrative expenses significantly increased to $706,257 in 2023.
• The company has a limited operating history and a history of losses.
• The company's stock trades on the OTC Pink Market, which is generally illiquid and volatile.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's ability to continue as a going concern is dependent on raising additional funds.

Risks

• The company has limited capital and may need to raise additional capital in the future, which could dilute current investors.
• The company's stock price is volatile and subject to various factors beyond its control.
• The company's stock is considered a penny stock, which limits broker-dealer solicitation and reduces liquidity.
• Changes to SEC Rule 15c2-11 could limit stock price, liquidity, or volume.
• The company's internal controls over financial reporting are ineffective due to material weaknesses.
• The company's ability to continue as a going concern is dependent on its ability to raise additional funds and generate sufficient revenue.
• The company faces competition in the health and wellness market.
• The company's reliance on related party advances poses a risk.

Future Outlook

The company plans to focus on gaining traction for its mental health and general wellness products, leveraging its patent-pending Methylene Blue products and other specialty offerings. They intend to raise additional capital through a private placement and file Form 1-A with the SEC. The company is also exploring potential partnerships and strategic alliances.

Management Comments

• As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings.
• We believe we are very well positioned and with adequate capital infusion we will be able to capitalize on multiple market opportunities.
• The Nowtransit management team plans to focus on gaining traction for its mental health and general wellness products.

Industry Context

The company is positioning itself in the growing health and wellness market, particularly in areas such as mental health, cognitive support, and immune health. The focus on Methylene Blue and natural products aligns with a trend towards alternative and preventative health solutions. The company is targeting a large and growing market for mental health products, with a specific focus on natural alternatives to prescription medications.

Comparison to Industry Standards

• Nowtransit's revenue growth from $69,343 to $597,595 year-over-year is significant, but it is important to compare this to other companies in the health and wellness sector, particularly those focused on online sales and natural products.
• Companies like Nutrafol, which focuses on hair health supplements, and Hims & Hers, which offers a range of telehealth and wellness products, have demonstrated rapid growth in the direct-to-consumer health space. However, these companies are significantly larger and have more established operations.
• The company's net loss of $251,500 is not unusual for an early-stage company, but it is important to monitor this metric and compare it to industry benchmarks for similar companies.
• The company's reliance on related party advances is a common practice for early-stage companies, but it is important to compare the terms and conditions of these advances to industry standards.
• The company's internal control weaknesses are a concern and should be addressed to meet industry standards for financial reporting.

Corporate Governance

Related Party Transactions

• The company purchased $157,010 worth of inventory from Ageless Holdings, LLC, an entity owned and controlled by the company's management and board of directors.
• The company received $613,973 in advances from Ageless and other related entities to pay for operating expenses and inventory purchases.
• The company repaid $572,255 of the advances to related parties.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and potential loss of investment due to the company's financial challenges.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers may benefit from the company's innovative health products, but the company's long-term viability could affect product availability.
• Suppliers may face risks related to the company's ability to pay for goods and services.
• Creditors face risks related to the company's ability to repay debts.

Next Steps

• The company will continue to market and sell its products through online sales and various distribution channels.
• The company will complete a private placement to raise up to $1,000,000.
• The company will begin the process of preparing and filing Form 1-A with the SEC.
• The company will focus on gaining traction for its mental health and general wellness products.
• The company will explore potential partnerships and strategic alliances to monetize and capitalize for the stakeholder.
• The company plans to rectify the identified material weaknesses in internal control over financial reporting by implementing an independent Board of Directors, establishing written policies and procedures, and hiring additional accounting personnel.

Key Dates

Keywords

Methylene Blue, Reverse Merger, Health Products, OTC Pink Market, Internal Control, Private Placement, Mental Health, Wellness, Penny Stock, Financial Reporting